About AqueSys
AqueSys is a company based in Aliso Viejo (United States) founded in 2006 was acquired by Allergan in September 2015. AqueSys has raised $87.6 million across 4 funding rounds from investors including The Carlyle Group, Allergan and Accuitive Medical Ventures. AqueSys operates in a competitive market with competitors including Glaukos, Ivantis, Myra Vision, Transcend Medical and InnFocus, among others.
- Headquarter Aliso Viejo, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$87.6 M (USD)
in 4 rounds
-
Latest Funding Round
$43.6 M (USD), Series D
Jan 16, 2014
-
Investors
The Carlyle Group
& 5 more
-
Employee Count
Not available
-
Acquired by
Allergan
(Sep 03, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of AqueSys
AqueSys has successfully raised a total of $87.6M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $43.6 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AqueSys
AqueSys has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include The Carlyle Group, Allergan and Accuitive Medical Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage US healthcare investments are made by Accuitive Medical Ventures.
|
Locked | Locked | Locked | |
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked |
Investor details for AqueSys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AqueSys
Investment portfolio details for AqueSys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AqueSys
Detailed financials for AqueSys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aquesys Comparisons
Peer comparison for AqueSys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AqueSys
AqueSys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Glaukos, Ivantis, Myra Vision, Transcend Medical and InnFocus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of implants to treat glaucoma
|
|
| Locked | Locked | Locked |
Implantable device to relieve intraocular pressure in open angle glaucoma
|
|
| Locked | Locked | Locked |
Nanotechnology-based devices for glaucoma treatment are developed.
|
|
| Locked | Locked | Locked |
Minimally invasive glaucoma stents are developed to enhance aqueous outflow.
|
|
| Locked | Locked | Locked |
Glaucoma is treated via the implantable MicroShunt device in ophthalmology.
|
Detailed competitors of AqueSys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aquesys
Complete news archive for AqueSys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AqueSys
AqueSys was founded in 2006 and raised its 1st funding round 2 years after it was founded.
AqueSys is headquartered in Aliso Viejo, United States. It is registered at Aliso Viejo, California, United States.
AqueSys is a funded company, having raised a total of $87.6M across 4 funding rounds to date.
AqueSys was founded in 2006 in Aliso Viejo, United States, as an ophthalmic company. Focus is placed on implantable devices to manage glaucoma. The XEN Gel Stent, a gelatin-based implant for intraocular pressure control, was developed and received CE Mark approval in Europe. Injection occurs via a preloaded device through a self-sealing incision. Acquisition by Allergan took place in 2015, with US approval pending at that time.
AqueSys's top competitors include Glaukos, Myra Vision and Avisi Technologies.
AqueSys has 6 investors. Key investors include The Carlyle Group, Allergan, Accuitive Medical Ventures, Longitude Capital, and SV Health Investors.